Hauttumore | ICD10: C43, C44, D03, D04
Sie befinden sich hier:
Studien offen zur Rekrutierung
ADMEC-O CA184-205137 kB
Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With 3 mg/kg BW Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation
AMGEN MASTERKEY-265_Talimogene Laherparepvec131 kB
A Phase 1b/3, Multicenter, Open-label Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresected, Stage IIIB to IVM1c Melanoma
BMS NivoPass_CA209-23471 kB
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
COMBI-r266 kB
Beobachtungsstudie zu Sicherheit und Effizienz von Dabrafenib und Trametinib im klinischen Alltag (COMBI-r)
CV-8102-008_ Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC (in Vorbereitung)252 kB
Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma
Dynavax DV3-MEL-01_Keynote 184240 kB
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
EORTC Studie 1208 Minitub121 kB
Minitub: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation
IMMUNED135 kB
A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease - IMMUNED
ImmunoCobiVem156 kB
Bestimmung der Wirksamkeit und Sicherheit von Cobimetinib plus Vemurafenib gefolgt von dem PD-L1-Antikörper Atezolizumab bei Patienten mit inoperablem oder metastasiertem Melanom mit BRAFV600 Mutation.
NICCI StudieA Phase II, single-armed, multicenter Trial of neoadjuvant vismodegib in patients with large and/or recurrent basal cell carcinoma (NICCI)
Novartis Triple- Studie/Combi I CPDR001F2301104 kB
A randomized, double-blind, placebo-controlled, phase IIIstudy comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma
PH-L19IL2TNF-02/15267 kB
A pivotal Phase III, open-label, randomized, controlled multi-center study of the efficacy of L19IL2/L19TNF neoadjuvant intratumoral treatment followed by surgery versus surgery alone in clinical stage III B/C melanoma patients
PV-10-MM-31_ Intralesional Injection267 kB
PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional OncolyticViral Therapy for Treatment of Locally Advanced Cutaneous Melanoma without Distant Metastases
Regeneron143 kB
A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma
RESMAIN Studie152 kB
A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study
Roche coveNISEine nicht-interventionelle Studie zur Untersuchung der Sicherheit, Wirksamkeit und Anwendung von Cobimetinib und Vemurafenib bei Patienten mit BRAF-V600-MutationPositivem Melanom mit und ohne Hirnmetastasen in der alltäglichen Praxis. (ML 39302)
SVM9122A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanom
TREAT20plusValidation of the virtual patient to optimise individual therapy for patients with metastatic melanoma
Trilogy151 kB
A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Xenograft_HTCCSammlung von MM-Filiae zur Eablierung von Xenografts